10 19

Cited 0 times in

Cited 0 times in

Survival Outcomes of Open Versus Robot-Assisted Radical Cystectomy: A Large-Scale Multicenter Propensity Score Matched Study

Authors
 Park, Jong Ho  ;  Lee, Sangchul  ;  Jeong, Seung-Hwan  ;  Ku, Ja Hyeon  ;  Kim, Kyung Hwan  ;  Nam, Jong Kil  ;  Lim, Bumjin  ;  Hong, BumSik  ;  Nam, Wook  ;  Kang, Sung Gu  ;  Kang, Seok Ho  ;  Kwon, Tae Gyun  ;  Kim, Tae-Hwan  ;  Heo, Jieun  ;  Ham, Won Sik  ;  Song, Geehyun  ;  Seo, Ho Kyung  ;  Song, Wan  ;  Sung, Hyun Hwan  ;  Jeong, Byong Chang  ;  Oh, Jong Jin 
Citation
 JOURNAL OF CLINICAL MEDICINE, Vol.15(9), 2026-05 
Article Number
 3559 
Journal Title
JOURNAL OF CLINICAL MEDICINE
Issue Date
2026-05
Keywords
urinary bladder neoplasms ; cystectomy ; robotic surgical procedures ; survival analysis ; propensity score
Abstract
Background/Objectives: While robot-assisted radical cystectomy (RARC) is widely adopted, its long-term survival impact relative to open radical cystectomy (ORC) remains uncertain. We compared survival outcomes between ORC and RARC using a propensity score-matched multicenter cohort. Methods: We retrospectively analyzed 3972 radical cystectomy patients from 11 Korean tertiary centers between 2003 and 2024. After stratifying by surgical approach (ORC vs. RARC), 1:1 propensity score matching (PSM) mitigated baseline imbalances. Overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were evaluated using Kaplan-Meier and multivariable Cox analyses. Results: PSM yielded 473 well-balanced patients per group. Compared to ORC, RARC was associated with a longer operative time but demonstrated a superior perioperative profile, including reduced estimated blood loss, lower intraoperative transfusion rates, shorter hospital stays, higher lymph node yields, and lower positive margin rates. RARC significantly improved OS (5-year: 75.4% vs. 56.1%; 10-year: 68.3% vs. 44.5%; p < 0.001) and CSS (5-year: 88.1% vs. 71.6%; 10-year: 82.7% vs. 67.7%; p < 0.001), with comparable RFS (5-year: 59.6% vs. 54.8%; 10-year: 51.1% vs. 47.4%; p = 0.155). Multivariable analyses confirmed RARC as an independent predictor of improved OS (hazard ratio [HR] 0.564, p < 0.001) and CSS (HR 0.474, p < 0.001). Conclusions: RARC demonstrated superior perioperative outcomes and favorable survival trends compared to ORC, with no difference in RFS. Although RARC appears to be an oncologically safe alternative, these exploratory survival benefits require cautious interpretation due to potential residual confounding. Further prospective validation is warranted.
Files in This Item:
93170.pdf Download
DOI
10.3390/jcm15093559
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Ham, Won Sik(함원식) ORCID logo https://orcid.org/0000-0003-2246-8838
Heo, Ji Eun(허지은) ORCID logo https://orcid.org/0000-0002-4184-8468
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/212636
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links